Deep TMS trial pairs trauma exposure with prefrontal stimulation for PTSD-related suicidal ideation
A new deep transcranial magnetic stimulation study is setting out to test whether neuromodulation can ease one of the most dangerous clinical features of post-traumatic stress disorder: active suicidal ideation. The protocol centers on adults with PTSD who are already symptomatic despite standard care, and it uses the H1-coil to deliver high-frequency stimulation to prefrontal targets thought to shape fear extinction, emotional regulation, and impulse control.
The design is unusual in a clinically meaningful way. Each stimulation session is preceded by a brief script-driven exposure procedure intended to activate trauma-related neural circuits before the magnetic pulses begin. In practical terms, the approach tries to bring the relevant brain networks online first, then push them toward a more adaptive response pattern through stimulation. The strategy reflects a mechanistic bet that timing the intervention to the patient’s trauma circuitry may matter as much as the stimulation itself.
Why the protocol focuses on suicidal ideation and PTSD together
PTSD is not only a disorder of intrusive memories and hyperarousal. It also carries a substantial burden of functional decline, emotional numbing, avoidance, and suicide risk. For patients who continue to experience severe symptoms after selective serotonin reuptake inhibitors, trauma-focused psychotherapy, or both, the treatment gap can become clinically dangerous. Some patients do not respond adequately. Others cannot tolerate exposure-based psychotherapy long enough to benefit from it.
This study is built around that gap. Rather than treating suicidal ideation as a secondary concern, the primary endpoint measures change in suicidal ideation severity using the Beck Scale for Suicide Ideation, a 0-to-38 scale in which higher scores indicate worse symptom burden. That focus gives the trial immediate bedside relevance. A reduction in suicidal thinking would not simply represent symptom improvement on paper; it would signal a possible shift in imminent risk for a population that often presents with overlapping trauma symptoms, depressive burden, and treatment resistance.
The protocol also reflects a neuroscience rationale that has been present in prior feasibility work. Deep TMS with the H1-coil is designed to reach deeper cortical regions than standard coils, including areas in the lateral prefrontal cortex implicated in PTSD symptom expression and extinction learning. The prefrontal cortex is central to top-down control over threat processing, and dysfunction in these circuits can leave traumatic memories emotionally raw and persistently reactive. In that context, a noninvasive intervention aimed at those networks is biologically plausible.
A brief exposure task before each session may amplify that plausibility. Trauma-related activation could transiently engage the same circuits that drive distress, then make them more receptive to extinction-based modulation during stimulation. The study is not claiming that mechanism as proven. It is testing whether the combination can produce measurable clinical change in a carefully selected cohort.
Enrollment, timing, and who can participate
The trial is estimated to enroll 72 participants and is designed as a single-group, open-label interventional study. It is not randomized, and it does not include masking. The estimated study start is 2026-10, with primary completion projected for 2029-02 and full study completion for 2029-10.
Eligibility is tightly drawn. Adults ages 22 through 68 years with DSM-5 PTSD and active suicidal ideation confirmed by the Beck Scale for Suicide Ideation may qualify if they can provide informed consent and comply with study procedures. Stable psychiatric medication use for at least four weeks is required when applicable. Exclusions remove patients with psychosis, bipolar disorder, severe personality disorder, recent substance use disorder aside from nicotine or caffeine, significant neurologic disease, seizure history, TMS contraindications, pregnancy or breastfeeding, unstable medical illness, cognitive impairment that would interfere with participation, imminent need for a higher level of care, prior non-response to adequate TMS treatment, or recent participation in another interventional study.
The eligibility rules matter because safety is not a side issue in a suicidal population. TMS is generally considered noninvasive, but seizure threshold, neurologic history, and device-related contraindications still require careful screening. The trial also requires a stable medication regimen, which helps reduce confounding when changes in mood or suicidality are later interpreted.
The study outcomes extend beyond suicidal thinking
Suicidal ideation is the primary outcome, but the protocol follows a broader symptom profile. PTSD severity will be assessed with the Clinician-Administered PTSD Scale for DSM-5 and the PTSD Checklist for DSM-5. Depressive symptoms will be measured with the Hamilton Depression Rating Scale, 21-item version. These scales are collected at different points across screening, baseline, 2-week visits, post-treatment at 4 weeks, and follow-up visits at 1 and 2 months, depending on the instrument.
That structure is clinically sensible. Suicide risk rarely changes in isolation. In PTSD, suicidal thinking often travels with depression, persistent arousal, insomnia, shame, and emotional dysregulation. If the intervention helps, it should do more than blunt a single item on a scale. It should ideally move the broader syndrome.
There is also a subtler scientific reason for tracking multiple domains. PTSD and depression overlap, but they are not identical. A treatment that lowers suicidal ideation without touching core trauma symptoms could still be useful, yet it would imply a different mechanism than one that improves the full PTSD syndrome. The outcome battery will help clarify whether any signal looks like focused anti-suicidal benefit, broader PTSD relief, or both.
Open-label design leaves the central question unresolved
The study is prospectively structured, but the open-label, single-group format leaves a large interpretive gap. Without a control arm, any improvement will be difficult to separate from expectancy effects, spontaneous fluctuation, regression to the mean, or the simple passage of time in a highly symptomatic population. The absence of masking adds another layer of uncertainty, particularly for subjective outcomes such as suicidal ideation and self-reported PTSD symptoms.
The trial still has value. Early-stage work often begins with a design like this when investigators are trying to determine whether a biologically plausible intervention is tolerable, feasible, and capable of generating a signal strong enough to justify a larger controlled study. In a field where suicidal ideation can be difficult to treat and trauma-focused therapy is not always sustainable, even a modest effect would be clinically meaningful if it proves reproducible.
The study is being conducted in Beersheba, Israel, with contact points listed at Be’er Sheva Mental Health Center. Its sponsor is D.R. Rut Zaks OHAYON, and the record lists Rut Zaks-Ohayon, PhD, and Abraham Zangen, Professor, among the study contacts. The central unanswered issue remains whether pairing trauma activation with H1-coil deep TMS can produce a durable reduction in suicidal thinking without compromising safety. The protocol is built to find out, but the open-label design means the first readout will be only a first pass at the answer.